恒生医疗ETF(513060)反弹涨超1%，近2周新增规模居可比基金首位，我国创新药发展已进入政策红利密集释放期

Group 1: Market Performance - The Hang Seng Healthcare Index (HSHCI) increased by 1.64% as of July 11, 2025, with notable gains from companies like WuXi AppTec (up 9.84%) and Sihuan Pharmaceutical (up 7.22%) [3] - The Hang Seng Healthcare ETF (513060) rose by 1.04%, reaching a latest price of 0.58 yuan, and has accumulated a 3.21% increase over the past two weeks [3] - The trading volume for the Hang Seng Healthcare ETF was 1.85 billion yuan, with a turnover rate of 2.29% [3] Group 2: Company Earnings - WuXi AppTec announced an expected adjusted net profit of approximately 6.315 billion yuan for the first half of the year, representing a year-on-year growth of about 44.43% [3] - The company anticipates a net profit attributable to shareholders of approximately 8.561 billion yuan, a year-on-year increase of about 101.92%, which includes investment gains from the sale of equity in an associate [3] - The basic earnings per share for WuXi AppTec is projected to be around 3.01 yuan, reflecting a year-on-year growth of approximately 106.16% [3] Group 3: Industry Trends - According to GF Securities, China's innovative drug development has entered a phase of intensive policy support, with significant measures introduced by the National Healthcare Security Administration and the National Health Commission [4] - By the end of 2024, the number of original innovative drugs developed by Chinese companies reached 3,575, surpassing the United States and ranking first globally [4] - Over 30% of global collaborations with upfront payments exceeding 50 million USD in 2024 originated from China, indicating a growing recognition of Chinese innovative drugs by global pharmaceutical giants [4] Group 4: ETF Performance Metrics - The Hang Seng Healthcare ETF has seen a net value increase of 19.11% over the past two years [5] - The ETF's highest monthly return since inception was 28.34%, with an average monthly return of 6.82% [5] - The ETF's Sharpe ratio for the past year was 2.07, indicating strong risk-adjusted returns [5] Group 5: Risk and Valuation - The Hang Seng Healthcare ETF has the lowest relative drawdown of 0.45% compared to its benchmark this year [6] - The ETF's management fee is 0.50%, and the custody fee is 0.15% [6] - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Healthcare Index is 27.75, indicating a valuation below 89.82% of the historical data over the past three years [6]